74 related articles for article (PubMed ID: 21671350)
1. Cyclic adenosine 3',5'-monophosphate in rat steatotic liver transplantation.
Jimenez-Castro MB; Casillas-Ramirez A; Massip-Salcedo M; Elias-Miro M; Serafin A; Rimola A; Rodes J; Peralta C
Liver Transpl; 2011 Sep; 17(9):1099-110. PubMed ID: 21671350
[TBL] [Abstract][Full Text] [Related]
2. Hypothermic oxygenated perfusion with defatting cocktail further improves steatotic liver grafts in a transplantation rat model.
Lin F; Zhen F; Yan X; Shaojun Y; Guizhu P; Yanfeng W; Qifa Y
Artif Organs; 2021 Sep; 45(9):E304-E316. PubMed ID: 33908066
[TBL] [Abstract][Full Text] [Related]
3. Overcoming the hurdles of steatotic grafts in liver transplantation: Insights into survival and prognostic factors.
Akabane M; Imaoka Y; Esquivel CO; Melcher ML; Kwong A; Sasaki K
Liver Transpl; 2024 Apr; 30(4):376-385. PubMed ID: 37616509
[TBL] [Abstract][Full Text] [Related]
4. Single-cell profiling reveals distinct immune phenotypes that contribute to ischaemia-reperfusion injury after steatotic liver transplantation.
Yang X; Lu D; Wang R; Lian Z; Lin Z; Zhuo J; Chen H; Yang M; Tan W; Yang M; Wei X; Wei Q; Zheng S; Xu X
Cell Prolif; 2021 Oct; 54(10):e13116. PubMed ID: 34469018
[TBL] [Abstract][Full Text] [Related]
5. Ferrostatin-1 improves prognosis and regulates gut microbiota of steatotic liver transplantation recipients in rats.
Yuan M; Wang Y; Tian X; Zheng W; Zuo H; Zhang X; Song H
Future Microbiol; 2024 Mar; 19():413-429. PubMed ID: 38305222
[No Abstract] [Full Text] [Related]
6. ZBP1-mediated apoptosis and inflammation exacerbate steatotic liver ischemia-reperfusion injury.
Liu R; Cao H; Zhang S; Cai M; Zou T; Wang G; Zhang D; Wang X; Xu J; Deng S; Li T; Xu D; Gu J
J Clin Invest; 2024 May; ():. PubMed ID: 38743492
[TBL] [Abstract][Full Text] [Related]
7. Outcomes using steatotic liver grafts: Will machines score the final goal?
Pagano G; Fundora Y; Crespo G
Liver Transpl; 2024 Apr; 30(4):341-342. PubMed ID: 38009946
[No Abstract] [Full Text] [Related]
8. Letter to the Editor: Statement of steatotic liver disease-A great leap toward the global standardization.
Wang CC; Cheng YM; Kao JH
Hepatology; 2024 Jan; 79(1):E7-E8. PubMed ID: 37535804
[No Abstract] [Full Text] [Related]
9. Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake - Authors' reply.
Israelsen M; Rinella ME; Krag A
Lancet Gastroenterol Hepatol; 2024 May; 9(5):409-410. PubMed ID: 38604197
[No Abstract] [Full Text] [Related]
10. Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart.
Abdelmalek MF; Rinella ME
Hepatology; 2024 Jun; 79(6):1252-1254. PubMed ID: 38100309
[No Abstract] [Full Text] [Related]
11. Alcohol Intake Thresholds Among Individuals With Steatotic Liver Disease.
Yeo YH; Zhu Y; Arab JP; Ni W; Xu X; Shi J; Li J
JAMA Netw Open; 2023 Dec; 6(12):e2347548. PubMed ID: 38095900
[TBL] [Abstract][Full Text] [Related]
12. Commentary on New Fatty Liver Nomenclature: Steatotic Liver Disease.
Shetty A; Saab S
J Clin Gastroenterol; 2024 Feb; 58(2):109. PubMed ID: 38019052
[No Abstract] [Full Text] [Related]
13. Heart-liver axis implications of the new steatotic liver disease nomenclature.
Li P; Ji H; Cheng S
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1071-1072. PubMed ID: 37951235
[No Abstract] [Full Text] [Related]
14. The new international nomenclature for steatotic liver disease: One step forward towards enhanced awareness for healthier life.
van Erpecum KJ; van Kleef LA; Beuers U; de Knegt RJ
Eur J Intern Med; 2023 Nov; 117():1-2. PubMed ID: 37714774
[No Abstract] [Full Text] [Related]
15. Editorial: Social determinants of health in steatotic liver disease-Generating community-level data to maximise community impact.
Duarte MJ; Rubin JB
Aliment Pharmacol Ther; 2023 Sep; 58(5):552-553. PubMed ID: 37559516
[No Abstract] [Full Text] [Related]
16. Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives.
Krag A; Buti M; Lazarus JV; Allen AM; Bowman J; Burra P; Donnini G; Duseja A; El-Sayed MH; Gastaldelli A; Hainsworth B; Karlsen TH; Kessler M; Korenjak M; Mark HE; Mann JP; Miller V; Pessoa MG; Piñeiro D; Sarin SK; Singh SP; Rinella ME; Willemse J; Younossi ZM; Francque SM
J Hepatol; 2023 Nov; 79(5):1076-1078. PubMed ID: 37634993
[No Abstract] [Full Text] [Related]
17. Editorial: Crystalising the burden of steatotic liver disease.
Bertot LC; Adams LA
Aliment Pharmacol Ther; 2024 May; 59(10):1292-1293. PubMed ID: 38652765
[No Abstract] [Full Text] [Related]
18. Chronic hepatitis C related steatotic liver disease is more than "miscellaneous steatotic liver disease".
Huang CF; Yeh ML; Dai CY; Huang JF; Chuang WL; Yu ML
Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38729391
[No Abstract] [Full Text] [Related]
19. Reply: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
Neil DAH; Smith ML; Minervini M; Demetris AJ
Hepatology; 2024 Feb; ():. PubMed ID: 38349643
[No Abstract] [Full Text] [Related]
20. Letter to the Editor: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
Cao H; Gu J
Hepatology; 2024 Feb; ():. PubMed ID: 38349642
[No Abstract] [Full Text] [Related]
[Next] [New Search]
